Brokers Issue Forecasts for Neurogene FY2027 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.93) for the year. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Tuesday, March 24th. The company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.08.

A number of other equities analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Canaccord Genuity Group began coverage on Neurogene in a report on Friday, February 27th. They set a “buy” rating on the stock. Lifesci Capital began coverage on shares of Neurogene in a report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Neurogene Price Performance

NGNE opened at $21.41 on Friday. The business has a fifty day simple moving average of $19.46 and a 200 day simple moving average of $21.65. Neurogene has a 1 year low of $6.88 and a 1 year high of $37.27. The company has a market capitalization of $333.35 million, a PE ratio of -5.05 and a beta of 1.53.

Insider Transactions at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,045 shares of Neurogene stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the sale, the chief financial officer directly owned 105,798 shares in the company, valued at $2,201,656.38. This trade represents a 3.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stuart Cobb sold 6,797 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the sale, the insider directly owned 30,497 shares in the company, valued at $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 11.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neurogene

A number of institutional investors have recently made changes to their positions in NGNE. Balyasny Asset Management L.P. bought a new stake in Neurogene in the third quarter valued at approximately $12,114,000. Logos Global Management LP bought a new stake in Neurogene in the fourth quarter worth approximately $4,017,000. Jennison Associates LLC lifted its stake in Neurogene by 35.3% in the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares during the period. State Street Corp boosted its holdings in shares of Neurogene by 47.8% during the 4th quarter. State Street Corp now owns 307,797 shares of the company’s stock worth $6,341,000 after buying an additional 99,487 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Neurogene by 122.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 162,018 shares of the company’s stock worth $3,338,000 after buying an additional 89,216 shares during the period. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.